Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer. Issue 6 (1st June 2022)

• Record Type: Journal Article
• Authors: Qin, Miao; Chen, Gang; Hou, Jinxia; Wang, Li; Wang, Qunfeng; Wang, Lina; Jiang, Dan; Hu, Ye; Xie, Bei; Chen, Jing; Wei, Hulai; Xu, Guangxian
• Is Part Of: Bioengineered. Volume 13:Issue 6(2022)
• Page Start: 14872
• Page End: 14888
• Publication Date: 2022-06-01
• Subjects: CRC -- infiltrating features -- CD8+TILs -- prognosis value -- ICB response; Biomedical engineering -- Periodicals; Biotechnology -- Periodicals; Microbiology -- Periodicals; 660.6
• DOI: 10.1080/21655979.2022.2162660
• Languages: English
• ISSNs: 2165-5987

Abstract

ABSTRACT: Tumor-infiltrating lymphocytes (TILs) are vital elements of the tumor microenvironment (TME), and the anti-tumor activity of TILs on colorectal cancer (CRC) has been a topic of concern. However, the characteristics and prognosis of the various types of lymphocyte infiltration in CRC have not been fully explained. Our study aimed to identify distinct features and prognosis of TILs. We integrated multiple-cohort databases to illustrate the features, proportions, and prognosis of TILs on CRC. We found that macrophages were significantly enriched in CRC. When we used the scRNA-seq database to further evaluate the proportion of TILs, we noticed markedly higher numbers of CD4 + T cell, B cell, and CD8 + T cell in four Gene Expression Omnibus Series (GSE) CRC cohorts. Interestingly, we found that the infiltrating level of TIL subgroups from highest to lowest is always dendritic cells, CD8 + T cells, CD4 + T cells, neutrophils, B cells, and macrophages; the proportion of infiltration is largely constant regardless of mutations in specific genes or somatic copy number variation (sCNV). In addition, the data corroborated that CD4+ TILs and CD8+ TILs have certain application values in the prognosis of CRCs, and age negatively related to CD8+ TILs and B plasma infiltration. Finally, patients with CRC who are older than 70 years have a better response to immune-checkpoint blockade. Graphic Abstract: uf0001